Maria Skoog

Copenhagen, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).

Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).

Journal: The Cochrane database of systematic reviews

Published: December 04, 2025

Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).

Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).

Journal: The Cochrane database of systematic reviews

Published: March 27, 2023

Antibiotics for secondary prevention of coronary heart disease.

Antibiotics for secondary prevention of coronary heart disease.

Journal: The Cochrane database of systematic reviews

Published: March 11, 2021

Social skills training for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years.

Social skills training for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years.

Journal: The Cochrane database of systematic reviews

Published: June 22, 2019

Hallucinations and other psychotic symptoms in response to methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder: a Cochrane systematic review with meta-analysis and trial sequential analysis.

Hallucinations and other psychotic symptoms in response to methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder: a Cochrane systematic review with meta-analysis and trial sequential analysis.

Journal: Scandinavian journal of child and adolescent psychiatry and psychology

Published: July 10, 2018

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.

Journal: The Cochrane database of systematic reviews

Published: May 11, 2018

Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.

Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.

Journal: The lancet. Psychiatry

Published: November 02, 2016

Gastrointestinal adverse events during methylphenidate treatment of children and adolescents with attention deficit hyperactivity disorder: A systematic review with meta-analysis and Trial Sequential Analysis of randomised clinical trials.

Gastrointestinal adverse events during methylphenidate treatment of children and adolescents with attention deficit hyperactivity disorder: A systematic review with meta-analysis and Trial Sequential Analysis of randomised clinical trials.

Journal: PloS one

Published: October 18, 2016

Response to "Trust, but verify" by Banaschewski et al.

Response to "Trust, but verify" by Banaschewski et al.

Journal: Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie

Published: September 24, 2016

Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials.

Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials.

Journal: BMJ (Clinical research ed.)

Published: November 27, 2015

Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).

Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).

Journal: The Cochrane database of systematic reviews

Published: November 25, 2015

Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised, blinded clinical trial.

Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised, blinded clinical trial.

Journal: International journal of cardiology

Published: September 10, 2014

Showing 1-12 of 19

Last Updated: 09/26/2026